- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00201747
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Phase II Randomized Trial of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale: Previous studies suggest that both irinotecan and Mytomycin C when administered alone have some efficacy against stomach cancer. Based on laboratory testing, researchers hypothesized that Mytomycin C may enhance the efficacy of irinotecan through an enzyme called Topoisomerase I. In addition, because Mytomycin C has severe side effects, combining these chemotherapy agents together may allow for lower dosages resulting in greater efficacy and reduced side effects. A recent study indicates that the combination of these drugs has promising anti-tumor activity against esophageal and stomach cancers. The current study builds on previous research to explore the most effective schedule for administering these drugs together.
Purpose: This study is evaluating the combination of irinotecan and Mytomycin C on two different treatment schedules in patients with advanced esophageal and stomach cancers. Characteristics of different genes will also be measured, along with genetic and molecular changes by comparing test results from the beginning and end of the study.
Treatment: Patients in this study will receive irinotecan and Mytomycin C in one of two treatment schedules. Both drugs will be administered in patients through an intravenous infusion. A computer will randomly assign patients to a treatment group. Group one will receive Mytomycin C on day 1 and irinotecan on days 2 and 9. Group two will receive Mytomycin C on days 1 and 8 and irinotecan on days 2 and 9. After day 9, patients in both groups will not be given any study drugs for almost three weeks to complete a four week cycle. Several tests and exams will be given throughout the study to closely monitor patients. Patients will continue receiving the study drugs until they experience disease growth or unacceptable side effects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must have pathologically confirmed & measurable advanced esophageal or Gastroesophageal junction adenocarcinoma
- No prior chemotherapy
- Prior radiation allowed if <=20% of bone marrow was irradiated
- Target lesions must not be in radiation field.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas
Time Frame: 2001-2010
|
2001-2010
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate gene expression profile of NQ01, and Topo I genes in peripheral blood mononuclear cells and tumor tissue during therapy with MMC and CPT-11
Time Frame: 2001-2010
|
2001-2010
|
Evaluate the frequency of NQ01 gene mutations in patients with esophageal and GE junction adenocarcinomas and its association to prognosis and antitumor activity.
Time Frame: 2001-2010
|
2001-2010
|
Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity.
Time Frame: 2001-2010
|
2001-2010
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Miguel Villalona, MD, Ohio State University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Stomach Neoplasms
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antibiotics, Antineoplastic
- Mitomycins
- Mitomycin
Other Study ID Numbers
- OSU-0151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Cancer
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
BayerCompletedPrevention of Oesophagus Cancer and Stomach CancerUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Genentech, Inc.; SCRI Development Innovations... and other collaboratorsCompletedStomach Cancer | Gastric Cancer | Esophageal CancerUnited States
-
MacroGenicsMerck Sharp & Dohme LLCCompletedStomach Cancer | Gastric Cancer | Esophageal CancerKorea, Republic of, United States, Taiwan, Singapore, Canada
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Genentech, Inc.; Brigham and Women's HospitalCompletedStomach Cancer | Esophageal CancerUnited States
-
Enzon Pharmaceuticals, Inc.TerminatedCancer of Stomach | Gastroesophageal Cancer
Clinical Trials on CPT-11
-
Daiichi Sankyo Co., Ltd.CompletedMetastatic Colorectal CancerJapan
-
Kazuhiko YoshimatsuHuman Genome Center, Institute of Medical Science, University of TokyoCompletedColorectal CancerJapan
-
Icahn School of Medicine at Mount SinaiRecruiting
-
JenKem Technology Co., Ltd.Completed
-
University of California, San FranciscoCompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States
-
Taiho Pharmaceutical Co., Ltd.Daiichi Sankyo Co., Ltd.Completed
-
Spanish Cooperative Group for the Treatment of...AmgenCompletedMetastatic Colorectal CancerSpain
-
National Cancer Institute (NCI)CompletedRefractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditionsUnited States, Canada
-
Assiut UniversityActive, not recruiting
-
National Cancer Institute (NCI)Active, not recruitingErlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsAdult Solid NeoplasmUnited States